利用 2 型糖尿病的异质性。
Harnessing heterogeneity in type 2 diabetes mellitus.
机构信息
Departments of Medicine, University of Chicago, Chicago, IL, USA.
Department of Pediatrics, University of Chicago, Chicago, IL, USA.
出版信息
Nat Rev Endocrinol. 2020 Feb;16(2):79-80. doi: 10.1038/s41574-019-0308-1.
Abstract
Personalized, or precision, medicine in type 2 diabetes mellitus is becoming a reality with new insights into the contributions of subgroup analyses. The roadmap to future implementation must take into account individual and subgroup variability in genetic architecture, environment, clinical measures, lifestyle, cost-effectiveness and treatment burden.
摘要
在 2 型糖尿病中，个体化或精准医学正随着对亚组分析贡献的新认识而成为现实。未来实施的路线图必须考虑遗传结构、环境、临床指标、生活方式、成本效益和治疗负担方面的个体和亚组差异。
相似文献
1
Harnessing heterogeneity in type 2 diabetes mellitus.利用 2 型糖尿病的异质性。
Nat Rev Endocrinol. 2020 Feb;16(2):79-80. doi: 10.1038/s41574-019-0308-1.
2
Moving towards a more precise treatment of diabetes.迈向更精准的糖尿病治疗。
Lancet Diabetes Endocrinol. 2015 Mar;3(3):171. doi: 10.1016/S2213-8587(15)00010-8.
3
Personalized medicine of type 2 diabetes.2型糖尿病的个性化医疗
Front Med. 2013 Mar;7(1):1-3. doi: 10.1007/s11684-013-0241-y.
4
Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.过氧化物酶体增殖物激活受体（PPAR）-γ激动剂治疗线粒体糖尿病
Intern Med. 2016;55(9):1143-7. doi: 10.2169/internalmedicine.55.4418. Epub 2016 May 1.
5
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.过氧化物酶体增殖物激活受体-γ（PPAR-γ）激动剂对血糖控制、血脂谱和心血管风险的影响。
Curr Mol Pharmacol. 2012 Jun;5(2):272-81. doi: 10.2174/1874467211205020272.
6
PPAR-γ action: it's all in your head.过氧化物酶体增殖物激活受体γ的作用：全在你的大脑里。
Nat Med. 2011 May;17(5):544-5. doi: 10.1038/nm0511-544.
7
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?噻唑烷二酮类药物在 2 型糖尿病治疗中仍有作用吗？
Diabetes Obes Metab. 2013 Nov;15(11):967-77. doi: 10.1111/dom.12101. Epub 2013 Apr 18.
8
Future directions for insulin sensitizers in disease prevention.胰岛素增敏剂在疾病预防方面的未来发展方向。
Curr Opin Investig Drugs. 2007 Sep;8(9):707-10.
9
Advances on PPARγ Research in the Emerging Era of Precision Medicine.精准医学新时代中 PPARγ 研究的进展
Curr Drug Targets. 2018;19(6):663-673. doi: 10.2174/1389450118666170622091333.
10
Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.发现和开发选择性过氧化物酶体增殖物激活受体γ调节剂作为安全有效的抗糖尿病药物。
Expert Opin Investig Drugs. 2010 Apr;19(4):489-512. doi: 10.1517/13543781003640169.
引用本文的文献
1
Discovery of a novel binding pocket in PPARγ for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis.发现过氧化物酶体增殖物激活受体γ（PPARγ）中一个用于部分激动剂的新型结合口袋：基于结构的虚拟筛选鉴定人参皂苷Rg5为促进米色脂肪生成的部分激动剂。
Front Chem. 2025 May 8;13:1579445. doi: 10.3389/fchem.2025.1579445. eCollection 2025.
2
Updates of precision medicine in type 2 diabetes.2型糖尿病精准医学的进展
Camb Prism Precis Med. 2023 Apr 14;1:e24. doi: 10.1017/pcm.2023.12. eCollection 2023.
3
Whole-exome sequencing in familial type 2 diabetes identifies an atypical missense variant in the RyR2 gene.全外显子组测序在家族性 2 型糖尿病中鉴定出 RyR2 基因中的一种非典型错义变异。
Front Endocrinol (Lausanne). 2024 Feb 20;15:1258982. doi: 10.3389/fendo.2024.1258982. eCollection 2024.
4
Label-free quantitative proteomics analysis for type 2 diabetes mellitus early diagnostic marker discovery using data-independent acquisition mass spectrometry (DIA-MS).基于数据非依赖采集质谱（DIA-MS）的 2 型糖尿病早期诊断标志物发现的无标记定量蛋白质组学分析。
Sci Rep. 2023 Nov 27;13(1):20880. doi: 10.1038/s41598-023-48185-3.
5
Unsupervised Anomaly Detection to Characterize Heterogeneity in Type 2 Diabetes.无监督异常检测用于表征2型糖尿病的异质性。
AMIA Jt Summits Transl Sci Proc. 2023 Jun 16;2023:32-41. eCollection 2023.
6
Prioritization of genes associated with type 2 diabetes mellitus for functional studies.优先考虑与 2 型糖尿病相关的基因进行功能研究。
Nat Rev Endocrinol. 2023 Aug;19(8):477-486. doi: 10.1038/s41574-023-00836-1. Epub 2023 May 11.
7
Trialing precision medicine for type 2 diabetes.2型糖尿病的精准医学试验。
Nat Med. 2023 Feb;29(2):309-310. doi: 10.1038/s41591-022-02168-5.
8
Cluster analysis of Thai patients with newly diagnosed type 2 diabetes mellitus to predict disease progression and treatment outcomes : A prospective cohort study.泰国新诊断 2 型糖尿病患者的聚类分析预测疾病进展和治疗结局：一项前瞻性队列研究。
BMJ Open Diabetes Res Care. 2022 Dec;10(6). doi: 10.1136/bmjdrc-2022-003145.
9
The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.PPARγ 翻译为过氧化物酶体增殖物激活受体γ。
Biomolecules. 2022 Dec 8;12(12):1832. doi: 10.3390/biom12121832.
10
Understanding islet dysfunction in type 2 diabetes through multidimensional pancreatic phenotyping: The Human Pancreas Analysis Program.通过多维胰腺表型分析了解 2 型糖尿病中的胰岛功能障碍：人类胰腺分析计划。
Cell Metab. 2022 Dec 6;34(12):1906-1913. doi: 10.1016/j.cmet.2022.09.013. Epub 2022 Oct 6.
Zotero 插件